First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Kura Oncology (Nasdaq: KURA) announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib). Under Kura's collaboration and license agreement with Kyowa Kirin, the sale triggers a $135 million milestone payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. This payment represents a near-term cash inflow tied to commercialization activity for the newly approved therapy.
Positive
- $135 million milestone payment expected prior to year-end
- FDA approval for KOMZIFTI on November 13, 2025
- First U.S. commercial sale confirms product market entry
Negative
- None.
Details
News Market Reaction – KURA
On Dec 2, the day this news came out, KURA closed 2.71% below the previous close.
Data tracked by StockTitan Argus for the Dec 2 session.
Key Figures
- Milestone payment
- $135 million
- Triggered by first U.S. KOMZIFTI commercial sale under Kyowa Kirin collaboration
- Collaboration revenue
- $20.8 million
- Q3 2025 revenue from Kyowa Kirin partnership
- Net loss
- $74.1 million
- Q3 2025 net loss, $0.85 per share
- Cash & investments
- $549.7 million
- Liquidity as of September 30, 2025
- Deferred revenue
- $317.6 million
- Contract liabilities from collaboration as of September 30, 2025
- Prior milestone
- $30 million
- Milestone from Kyowa Kirin on first patient dosed in KOMET‑017
- WAC per month
- $48,500
- Wholesale acquisition cost for one‑month KOMZIFTI supply
- KOMET‑001 size
- 112 patients
- Pivotal trial supporting KOMZIFTI approval in R/R NPM1‑mutated AML
Historical Context
-
ASH 2025 combination data for KOMZIFTI showing strong activity and tolerability.
-
Announcement of virtual event to discuss ASH 2025 triplet combination data.
-
First U.S. KOMZIFTI sale triggering $135 million payment from Kyowa Kirin.
-
KOMZIFTI added as NCCN Category 2A option for NPM1-mutated AML.
-
FDA approval of KOMZIFTI for relapsed/refractory NPM1‑mutated AML.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
U.S. Food and Drug Administration regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Kura’s expectations regarding the receipt and timing of a milestone payment under its collaboration and license agreement with Kyowa Kirin and future development matters. Factors that may cause actual results to differ materially include risks related to Kyowa Kirin’s ability to make the expected milestone payment, including on the anticipated timing; risks associated with the commercialization of KOMZIFTI; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.